自愈水凝胶
医学
间充质干细胞
肾脏疾病
急性肾损伤
限制
临床试验
肾
再生医学
重症监护医学
干细胞
内科学
病理
生物
材料科学
高分子化学
机械工程
工程类
遗传学
作者
Jing Peng,Tinghang Yang,Shanshan Chen,Ningyue Deng,Xinyao Luo,Ruoxi Liao,Baihai Su
出处
期刊:Tissue Engineering Part B-reviews
[Mary Ann Liebert, Inc.]
日期:2023-10-11
卷期号:30 (3): 315-326
被引量:3
标识
DOI:10.1089/ten.teb.2023.0196
摘要
Kidney diseases are major global health problems, with high prevalence and mortality. However, current treatment strategies for kidney diseases fail to achieve satisfactory efficacy. Mesenchymal stem cell (MSC)-based therapy has been a promising strategy for treating kidney diseases. Preclinical studies have proven their safety and effectiveness in treating acute kidney injury (AKI) and chronic kidney disease (CKD), but the outcomes of clinical trials have shown very limited clinical efficacy. A variety of innovative approaches have been proposed to enhance the therapeutic potential of MSCs, and hydrogels are attractive candidates. Hydrogels are three-dimensional (3D) networks formed by hydrophilic polymers of natural or synthetic origin with diverse physical and chemical properties. They have been widely applied in the field of drug delivery and regenerative medicine, including MSC-based therapy. Many studies have proven that hydrogels can improve the therapeutic efficacy of MSCs for kidney diseases, but there are still challenges limiting the widespread application of this method. In this review, we introduce the application of MSCs in kidney diseases and the factors that influence therapeutic efficiency and focus on the beneficial effects of hydrogels in MSC-based therapy for AKI and CKD.
科研通智能强力驱动
Strongly Powered by AbleSci AI